Development of a new HISCL automated CXCL9 immunoassay.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
01 04 2023
01 04 2023
Historique:
received:
21
11
2022
accepted:
28
03
2023
medline:
4
4
2023
entrez:
3
4
2023
pubmed:
4
4
2023
Statut:
epublish
Résumé
C-X-C motif chemokine ligand 9 (CXCL9), a candidate biomarker, reflects type 1 (T1) inflammation pathology. Here, we report the analytical performance and clinical characteristics of a new CXCL9 reagent for a fully automated immunoassay device. We evaluated the limits of blank, detection, and quantitation (LoQ) along with other efficacy parameters, and the ability of the assay to report patient health, COVID-19 status, and the presence of asthma and/or interstitial lung diseases (ILDs). The coefficient of variation for 5-day total precision using two instruments was 7% across two controls, serum, and plasma panels. LoQ of 2.2 pg/mL suggested the efficacy of the assay in detecting T1 inflammation in plasma or serum; no cross-reactivity or interference was observed. We identified high serum CXCL9 levels in samples from patients with acute COVID-19 infections (n = 57), chronic bird-related hypersensitivity pneumonitis (n = 61), asthma (n = 194), and ILDs (n = 84) compared to healthy individuals (< 39.0 pg/mL). Furthermore, CXCL9 levels increased with age in asthma patients, and an opposite trend was observed for T2 inflammatory factors. These results suggest the utility of the automated CXCL9 immunoassay for measuring CXCL9 in clinical samples and reflect its role in T1 inflammation.
Identifiants
pubmed: 37005469
doi: 10.1038/s41598-023-32513-8
pii: 10.1038/s41598-023-32513-8
pmc: PMC10066986
doi:
Substances chimiques
Biomarkers
0
Chemokine CXCL9
0
Chemokine CXCL10
0
CXCL9 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5342Informations de copyright
© 2023. The Author(s).
Références
Eur Respir J. 2011 Aug;38(2):310-7
pubmed: 21233270
Eur Cytokine Netw. 2022 Jun 1;33(2):25-36
pubmed: 36266985
N Engl J Med. 2017 Sep 7;377(10):965-976
pubmed: 28877019
Respir Res. 2011 Sep 22;12:123
pubmed: 21939519
Exp Cell Res. 2011 Mar 10;317(5):620-31
pubmed: 21376175
Blood. 2014 Jan 30;123(5):786-93
pubmed: 24363401
Infect Dis Poverty. 2020 May 11;9(1):51
pubmed: 32393333
Cytokine. 2011 Aug;55(2):288-93
pubmed: 21601475
J Infect Dis. 2017 Jan 1;215(1):42-51
pubmed: 28077582
JCI Insight. 2017 Jul 6;2(13):
pubmed: 28679952
Front Immunol. 2018 Jan 15;8:1970
pubmed: 29379506
Cytokine. 2021 Dec;148:155618
pubmed: 34127355
PLoS One. 2020 Nov 2;15(11):e0241719
pubmed: 33137121
Am J Respir Crit Care Med. 2010 Feb 15;181(4):315-23
pubmed: 19892860
Int J Mol Sci. 2022 Sep 19;23(18):
pubmed: 36142860
PLoS One. 2019 Aug 1;14(8):e0220462
pubmed: 31369605
Nat Med. 2012 May 04;18(5):716-25
pubmed: 22561835
Allergy. 2020 Feb;75(2):311-325
pubmed: 31309578
Am J Respir Crit Care Med. 2009 Sep 1;180(5):388-95
pubmed: 19483109
Eur J Dermatol. 2015 Jan-Feb;25(1):87-9
pubmed: 25547780
Respir Res. 2008 Dec 16;9:82
pubmed: 19087279
AIDS. 2016 Jan;30(2):327-30
pubmed: 26186129
Eur Cytokine Netw. 2017 Mar 1;28(1):8-18
pubmed: 28840844
Br J Haematol. 2014 Feb;164(3):329-41
pubmed: 24164387
Allergy. 2019 Dec;74(12):2515-2518
pubmed: 31125435